These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31628571)

  • 1. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD.
    Abreu MT
    Dig Dis Sci; 2019 Dec; 64(12):3377-3381. PubMed ID: 31628571
    [No Abstract]   [Full Text] [Related]  

  • 2. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary.
    Mountifield R
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():25-26. PubMed ID: 33817852
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
    Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
    Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
    Alsoud D; Vermeire S; Verstockt B
    Curr Opin Pharmacol; 2020 Dec; 55():17-30. PubMed ID: 33039940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of biologics in the treatment of patients with inflammatory bowel disease.
    Selinger CP; Carbery I; Al-Asiry J
    Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
    Dutt K; Vasudevan A
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
    [No Abstract]   [Full Text] [Related]  

  • 9. Next-Generation Therapeutics for Inflammatory Bowel Disease.
    Dulai PS; Sandborn WJ
    Curr Gastroenterol Rep; 2016 Sep; 18(9):51. PubMed ID: 27461274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.
    Hemperly A; Sandborn WJ; Vande Casteele N
    Inflamm Bowel Dis; 2018 Nov; 24(12):2527-2542. PubMed ID: 29788338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
    Conrad MA; Kelsen JR
    Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
    Restellini S; Khanna R; Afif W
    Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug monitoring of biologics in inflammatory bowel disease.
    Eser A; Primas C; Reinisch W
    Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease.
    Detrez I; Van Stappen T; Martín Arranz MD; Papamichael K; Gils A
    Ther Drug Monit; 2017 Aug; 39(4):344-349. PubMed ID: 28328760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed drug reaction to amiodarone characterized by sequential immediate, immune complex, and delayed hypersensitivity.
    Fernando SL; Li J; Jain A; Weir C; Boyle T
    Ann Allergy Asthma Immunol; 2020 Jul; 125(1):102-103. PubMed ID: 32283252
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
    Roblin X; Nancey S
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1453-1454. PubMed ID: 37243465
    [No Abstract]   [Full Text] [Related]  

  • 17. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
    Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
    Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety comparison of therapies used in inflammatory bowel disease.
    Pudipeddi A
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():20-21. PubMed ID: 33817854
    [No Abstract]   [Full Text] [Related]  

  • 19. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
    Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
    [No Abstract]   [Full Text] [Related]  

  • 20. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.